Latest clinical evidence about the effect of PCSK9 monoclonal antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis.
Endokrynol Pol
; 73(1): 110-120, 2022.
Article
en En
| MEDLINE
| ID: mdl-35381104
ABSTRACT
INTRODUCTION:
Familial hypercholesterolaemia (FH) is the most common autosomal genetic disease of cholesterol metabolism disorder. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody (mAb) is a new target lipid-regulating drug related to cholesterol metabolism that has been developed in recent years. The reported rate of reduction varies widely, and comprehensive assessments of efficacy and safety are lacking. Therefore, we conducted this study to investigate the clinical effect of PCSK9 mAbs in patients with familial hypercholesterolaemia to provide a theoretical reference for clinical practice. MATERIAL ANDMETHODS:
We analysed the clinical data of patients, including the percentage change in LDL-C and the incidence rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), from selected articles. Weighted mean differences (WMDs), risk ratios (RRs), and 95% confidence intervals (95% CIs) were calculated to compare the endpoints.RESULTS:
The results showed that, compared with placebo, the PCSK9 mAb reduced the percentage change in LDL-C in FH patients (WMD = -45.52, 95% CI -49.70 to -41.34, I2 = 99.6%). In addition, there was no significant difference between the experimental and placebo groups in the incidence of TEAEs (RR = 1.03, 95% CI 0.97 to 1.10, I2 = 19.1%) and SAEs (RR = 1.02, 95% CI 0.72 to 1.44, I2 = 0.0%).CONCLUSIONS:
Overall, PSCK9 mAbs are an effective and safe method of LDL-C reduction in patients with FH.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Hiperlipoproteinemia Tipo II
/
Anticolesterolemiantes
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
Endokrynol Pol
Año:
2022
Tipo del documento:
Article